{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:30:31Z","timestamp":1789878631490,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Real\u2010world data are needed to evaluate treatment implementation, outcomes and costs of care in haemophilia patients switching prophylaxis from standard half\u2010life (SHL) to extended half\u2010life (EHL) clotting factor concentrates (CFCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We characterised treatment regimens, annual bleeding rate (ABR), adherence and costs in a nationwide Finnish haemophilia A (HA) and B (HB) cohort on prophylaxis, including non\u2010switchers and switchers from SHL to EHL CFC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective register study of adult patients with HA and HB was performed in University Hospitals during 2016\u20132021. Clinical and healthcare data were captured from electronic health records and national healthcare registers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Majority, 74% of HA and 71% of HB patients, switched from SHL to EHL. Thereafter, weekly mean infusions of CFC decreased (FVIII SHL 2.8, EHL 2.2; FIX SHL 1.6, EHL 0.9;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). The mean annual consumption (international units, IU) increased by 18% from 219,534 per HA patient during SHL to 258,317 during EHL (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05) and declined per HB patient by 28% from 221,685 to 160,209 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01). ABR appeared to decline after the switch in HA (mean SHL 2.8, EHL 0.9) and HB (SHL 1.6, EHL 0.8), while treatment adherence improved in HA from 81% to 95% (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01). The mean annual total costs of care in HA were \u20ac176,979 for SHL and \u20ac195,760 for EHL. In HB, the costs increased from \u20ac180,930 to \u20ac236,208 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Majority of patients on prophylaxis switched to EHL. The switch alleviated the infusion regimen, tended to lower bleeding rates and improved adherence with somewhat increased costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70067","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:38:12Z","timestamp":1750477092000},"page":"722-733","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Switching From Standard to Extended Half\u2010Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland"],"prefix":"10.1111","volume":"31","author":[{"given":"Mirkka","family":"Koivusalo","sequence":"first","affiliation":[{"name":"MedEngine Oy  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-6564","authenticated-orcid":false,"given":"Timea","family":"Szanto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center Coagulation Disorders Unit Helsinki University Hospital  Helsinki Finland"},{"name":"Research Program Unit in Systems Oncology University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Kovalainen","sequence":"additional","affiliation":[{"name":"MedEngine Oy  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-9956","authenticated-orcid":false,"given":"Aino","family":"Vesikansa","sequence":"additional","affiliation":[{"name":"MedEngine Oy  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Laine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Tampere University Hospital  Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Partanen","sequence":"additional","affiliation":[{"name":"Department of Medicine Kuopio University Hospital  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Siitonen","sequence":"additional","affiliation":[{"name":"Department of Medicine Oulu University Hospital  Oulu Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Vesanen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Turku University Hospital  Turku Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"MedEngine Oy  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Sarnesto","sequence":"additional","affiliation":[{"name":"Novo Nordisk Farma Oy  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Haapkyl\u00e4","sequence":"additional","affiliation":[{"name":"Novo Nordisk Farma Oy  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u2010Elina","family":"Lehtinen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center Coagulation Disorders Unit Helsinki University Hospital  Helsinki Finland"},{"name":"Research Program Unit in Systems Oncology University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-3094","authenticated-orcid":false,"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center Coagulation Disorders Unit Helsinki University Hospital  Helsinki Finland"},{"name":"Research Program Unit in Systems Oncology University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12723"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1645002"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232132"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1571315"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6040039"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718796429"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14649"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13612"},{"key":"e_1_2_11_12_1","first-page":"374","article-title":"Optimising Prophylaxis Outcomes and Costs in Haemophilia Patients Switching to Recombinant FVIII\u2010Fc: A Single\u2010Centre Real\u2010World Experience","volume":"18","author":"Tagliaferri A.","year":"2020","journal-title":"Blood Transfusion"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25844"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000885"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01200-2"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02017-4"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302982"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216455"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573055"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-687434"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13432"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14369"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14307"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12661"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17070835"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13160"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.17212"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01774-9"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3398-x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100106"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1789457"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14197"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2073-y"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103678"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13970"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14201"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12301"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2022.2144923"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000011.pub4"},{"issue":"10","key":"e_1_2_11_42_1","first-page":"39","article-title":"Real\u2010World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half\u2010Life and Extended Half\u2010Life Products","volume":"27","author":"Chhabra A.","year":"2018","journal-title":"Managed Care (Langhorne Pa)"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.595"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:35:01Z","timestamp":1773002101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/hae.70067"],"URL":"https:\/\/doi.org\/10.1111\/hae.70067","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"2025-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}